Autobio Diagnostics Co., Ltd. (603658.SS) develops, manufactures, markets and services in vitro diagnostic reagents and instruments principally for immunoassay, microbiology, biochemistry, molecular diagnostics and coagulation testing; its core immunoassay offerings include chemiluminescence analyzers such as AutoLumo A6200/A6600 series, AutoLumo A2000 Plus, AutoLumo S900 and magnetic particle chemiluminescence reagents alongside ELISA and colloidal gold tests; microbiology products feature AutoMic-i600 ID-AST analyzer, AutoStreak S1800 sample pretreatment system, Autof T series and MALDI-TOF MS for pathogen identification, BC60/BC120 blood culture systems and susceptibility testing reagents; biochemistry lines comprise AutoChem B861/B2000 and Autolas Bi 1000/Bi2600 automated analyzers; molecular diagnostics cover AutoMolec 1600/3000 systems; coagulation analyzers include Ci-120x/Ci-310 models; and supporting services encompass technical support, training, internal quality control and AI-enhanced clinical decision systems for medical laboratories worldwide. Founded in 1998 and headquartered in Zhengzhou's National Eco & Tech Development Zone, China, the company operates domestically across thousands of medical institutions and exports to over 100 countries in Europe, Asia, the Middle East, South America and Africa, employing over 5,700 staff with R&D comprising about 30% and generating RMB 44.71 billion in 2024 revenue rising to RMB 31.27 billion in the first three quarters of 2025. Recent developments include strategic partnership with Boditech Med Inc in January 2025, hosting the Global MicroLabTalk Forum 2025 with IFCC and the 9th International Distributor Forum in Dubai, launching products like AutoLumo S900 and Autof T series at Medlab Middle East 2025, AutoChem B2000 winning the German iF Design Award 2025, expanding IVDR CE certificates to 326 and integrating DeepSeek-R1 AI into its clinical decision system; the firm listed on the Shanghai Stock Exchange main board in 2016 as China's first IVD manufacturer in that category.